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While the unique metabolic activities of malignant tissues as potential targets for cancer
therapeutics has been the subject of several recent reviews, the role of cholesterol
metabolism in this context is yet to be fully explored. Cholesterol is an essential component
of mammalian cell membranes as well as a precursor of bile acids and steroid hormones.
The hypothesis that cancer cells need excess cholesterol and intermediates of the
cholesterol biosynthesis pathway to maintain a high level of proliferation is well accepted,
however the mechanisms by which malignant cells and tissues reprogram cholesterol
synthesis, uptake and efﬂux are yet to be fully elucidated as potential therapeutic targets.
High and low density plasma lipoproteins are the likely major suppliers of cholesterol to
cancer cells and tumors, potentially via receptor mediated mechanisms. This review is
primarily focused on the role(s) of lipoproteins in carcinogenesis, and their future roles as
drug delivery vehicles for targeted cancer chemotherapy.
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INTRODUCTION
The term“cancer”designates a series of pathological changes char-
acterized by deregulation of cell cycle and metabolism resulting in
uncontrolled proliferation of cells (Teicher et al., 2012). While a
wide range of metabolic pathways have been implicated in the
process of carcinogenesis and (Hanahan and Weinberg, 2011) as
potential targets for cancer prevention, diagnosis or treatment,
relatively little has been written about the role(s) of cholesterol
biosynthesis or metabolism in this regard. This hiatus of informa-
tion is somewhat surprising as blood cholesterol levels [especially
high density lipoprotein (HDL) levels] have been consistently
shown to be lower in cancer patients (Ho et al., 1978; Vitols et al.,
1984, 1990) and tumor membranes were found to be rich in
cholesterol (Elegbede and Elson, 1986), suggesting that cholesterol
utilizationbymalignant cells and tumors is an important feature of
carcinogenesis and perhaps metastasis (Markel and Brook, 1994;
Antalis et al., 2011). While the speciﬁc mechanisms involved in
shifting normal cholesterol metabolism to the malignant phase
is not yet understood, clinical and experimental ﬁndings suggest
an apparent need of malignant cells and tissues for higher than
normal amounts of cholesterol (Murtola et al., 2012) and inter-
mediates of the cholesterol biosynthesis pathway (Mo and Elson,
2004). The purpose of this review is to provide an up to date
assessment of the ﬁndings involving cholesterol metabolism and
transport with a focus on opportunities for cancer therapeutics
and tumor imaging.
CHOLESTEROL AND CANCER
CHOLESTEROL HOMEOSTASIS IN NORMAL CELLS AND TISSUES
Cholesterol plays an essential role in the stability and architecture
of the plasma membrane and as a precursor for bile acid and
steroid hormone synthesis in mammals (Simons and Ikonen,
2000). Under healthy homeostatic conditions, the circulating lev-
els of cholesterol are regulated by a balance between local (cellular)
synthesis, dietary cholesterol and removal of the excess choles-
terol from peripheral tissues (Simons and Ikonen, 2000). The
disturbance of this homeostatic state is known to be associated
with cardiovascular diseases and is often attributed to dietary and
lifestyle habits (Hu et al., 2012). Clinical and experimental evi-
dence suggest that alterations in cholesterol metabolism may also
have an important role in carcinogenesis and tumor development
(Silvente-Poirot and Poirot, 2012b).
CHOLESTEROL METABOLISM IN CANCER
Carcinogenesis is a complex process that involves massive repro-
graming of genetic information, signaling mechanisms, structural
components, and energy metabolism (Hanahan and Weinberg,
2011; Biswas et al., 2012) of the cell. One could predict that
this major transformation process is the consequence of the can-
cer cell’s increased metabolic requirements (Warburg, 1956) to
sustain the tumor proliferation, migration and metastatic activ-
ities. Considering the importance and the efﬁcient regulation of
cholesterol metabolism and transport it is likely that these ﬁnely
tuned mechanisms will become altered during the high velocity of
cell division and membrane synthesis needed for carcinogenesis
(Silvente-Poirot and Poirot, 2012b).
Fluctuations of cellular and blood cholesterol levels are con-
trolled by a series of mechanisms that balance intracellular choles-
terol synthesis with mechanisms of uptake and efﬂux (Simons and
Ikonen, 2000; Solomon and Freeman, 2011). These mechanisms
also coordinate intracellular cholesterol levels with progressive
steps in the cell cycle (Simons and Ikonen, 2000; Pelton et al.,
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2012). The up-regulation of cholesterol biosynthesis and uptake
and the down-regulation or impairment of cholesterol efﬂux from
cells are considered to be consistentwith carcinogenesis. Hereinwe
provide a discussion of clinical and experimental data that reﬂect
on these mechanisms.
Enhanced cholesterol biosynthesis
Cholesterol is synthesized via a cascade of enzymatic reactions
known as the mevalonate pathway. This series of reactions is
primarily regulated by a rate-limiting step involving the conver-
sion of hydroxyl-methyl glutaryl-coenzyme A (HMG-CoA) into
mevalonate. The rate limiting reduction of HMG-CoA to meval-
onate is an important regulatory step in cholesterol synthesis that
is commonly used as therapeutic target in hyperlipidemic dis-
orders utilizing statin drugs. Studies of cancer cells reveal that
cholesterol synthesis is enhanced, compared to untransformed
cells (Larsson, 1996; Li et al., 2003; Mo and Elson, 2004; Clen-
dening et al., 2010; Ginestier et al., 2012). Among the possible
mechanisms that promote the upregulation of cellular cholesterol
synthesis are: the abundant availability of precursors (acetyl-CoA),
via glycolysis that also potentiates de novo fatty acid synthesis
(Warburg, 1956; DeBerardinis et al., 2008; Biswas et al., 2012).
Simultaneously, the activity of HMG-CoA reductase may also be
increased due to increased transcriptional regulation [mediated by
sterol regulatory element binding proteins (SREBPs)] or altered
feedback control of HMG-CoA reductase (Chen and Kandutsch,
1978; Gregg and Sabine, 1982; Yachnin and Mannickarottu, 1984;
Yachnin and Toub, 1984; Erickson and Cooper, 1988; Azrolan and
Coleman, 1989; Llaverias et al., 2011). In human PC-3 and LNCaP
prostate tumor cells, SREBP-2 activity had a strong correlation
with cell viability (Krycer and Phan, 2012). Consistent with the
above ﬁndings, the administration of mevalonate was shown to
enhance tumor growth inmice carrying tumor xenograft (Duncan
et al., 2004). Taken together these ﬁndings validate the importance
of the mevalonate pathway in cancer metabolism and identify a
target for potential novel therapeutic strategies via smallmolecules
or gene targeting.
Inhibition of the mevalonate pathway
Inhibition of the mevalonate pathway commonly taken advan-
tage during the treatment of dyslipidemic disorders. Statins are
competitive inhibitors of HMG-CoA reductase, thus blocking the
progression of the mevalonate pathway and limiting the down-
stream reactions and accumulation of the ﬁnal products: choles-
terol, isoprenoids, dolichol, ubiquinone, and isopentenyladenine
(Clendening et al., 2010; Thurnher et al., 2012).
Available experimental evidence strongly suggests that the inhi-
bition of the mevalonate pathway using statin drugs has an
impact on oncogenic events such as cell division, tumor growth,
and metastatic potential (Duncan et al., 2004; Clendening and
Penn, 2012; Thurnher et al., 2012). Inhibition of the mevalonate
pathway blocks the synthesis of isoprenoid molecules (farnesyl
pyrophosphate and geranylgeranyl pyrophosphate) that facilitate
post-translational modiﬁcation and activate Ras, Rac, and Rho
GTPases molecules contributing to tumor proliferation (Zhuang
et al., 2005; Solomon et al., 2009; Gorin et al., 2012). While statin
therapy blocks the intracellular synthesis of cholesterol, it also
alters the cholesterol content of tumor cell membranes, interfering
with key signaling pathways (Zhuang et al., 2005).
Because statins impact the early phase of the mevalonate path-
way, the potential therapeutic beneﬁts of statin therapymay hinder
cancer development by blocking cholesterol synthesis or pre-
venting the production of isoprenoids (non-steroid branch). In
addition, statins are known to have anti-inﬂammatory effects that
may also interfere with tumor growth and development.
Suppressors of the mevalonate pathway also include the diverse
isoprenoids (Mo and Elson, 2004), mevalonate-derived secondary
metabolites of plants (Bach, 1995). The potencies of isoprenoids in
suppressing hepatic HMG-CoA reductase activity was found to be
strongly correlated to their potencies in tumor suppression (Elson
and Qureshi, 1995). Most prominently, the tocotrienols, vitamin
E molecules and “mixed isoprenoids” with a farnesol side chain,
down-regulateHMG-CoA reductase activity in tumors and conse-
quently, induce cell cycle arrest and apoptosis (Mo and Elfakhani,
2013). Growth-suppressive effect of tocotrienols was attenuated
by supplemental mevalonate (Hussein and Mo, 2009).
Cholesterol accumulation in lipid rafts
The role of cholesterol in the plasma membranes is complex as it
extends beyond the modulation of the ﬂuidity and permeability
of the bilayer. Cholesterol is also known to accumulate in speciﬁc
regions of the membrane, combined with sphingolipids creat-
ing small, compartmentalized, and highly stable micro-domains
known as lipid-rafts. Lipid-rafts are referred to as the sites of
signaling platforms while their speciﬁc structure and function
depend on their respective lipid compositions and the target pro-
teins involved (Babina et al., 2011). Several proteins that associate
with lipid-rafts have been implicated in key signaling pathways
associated with malignant progression.
Apoptosis and cell cycle signaling. Other than the rapid prolif-
erative behavior of cancer cells, carcinogenic events also feature
inhibition/down-regulation of apoptotic pathways. Apoptosis is a
highly complex process of programmed cell death that involves
an energy-dependent cascade of signaling events (Elmore, 2007).
Apoptotic pathways can be classiﬁed into two main categories:
the extrinsic pathway (death receptor pathway) and the intrinsic
(mitochondrial pathway; Elmore, 2007; Babina et al., 2011). Inter-
estingly both of these pathways have been shown to be associated
with lipid rafts as they regulate apoptotic signaling events by mod-
ulating the cholesterol content of speciﬁc membrane regions (Li
and Park, 2006; Gajate et al., 2009).
Both Fas receptor (FasR) and TNF-related apoptosis-inducing
ligand (TRAIL) receptors 1 and 2, two classes of death receptors,
are dependent on translocation into lipid rafts to engage in effec-
tive signaling (Gajate et al., 2004; Elmore, 2007; Song et al., 2007).
By depleting the membrane of cholesterol, both TRAIL and Fas
mediated apoptosis was found to be downregulated (Song et al.,
2007; Gajate et al., 2009).
Akt is a serine-threonine speciﬁc protein kinase that mediates
cell survival and growth and its activation (via phosphorylation)
has been shown to occur via a cholesterol dependent mecha-
nism (Zhuang et al., 2002; Li and Park, 2006). In agreement with
these ﬁndings recent analysis of prostate cancer animal models
Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs September 2013 | Volume 4 | Article 119 | 2
“fphar-04-00119” — 2013/9/25 — 15:04 — page 3 — #3
Cruz et al. Cholesterol transport and cancer
revealed that elevations of plasma cholesterol cause accumu-
lations of cholesterol in lipid rafts and consequently leads to
reduced apoptosis and increased tumor growth via Akt signal-
ing (Li and Park, 2006; Adam et al., 2007; Llaverias et al., 2011;
Pelton et al., 2012). In addition, increasing cholesterol levels in
lipid-rafts appears to enhance Akt signaling both in vitro and
in vivo and therefore inducing (cancer) cell survival (Zhuang
et al., 2005). Recent studies also show that the subpopulation
of Akt present in lipid rafts shows signiﬁcantly higher sub-
strate speciﬁcity compared to the normal Akt (Pommier et al.,
2010).
Tumor growth and development. Several types of cancer cells
exhibit up-regulation of growth factor receptors (Normanno et al.,
2006). Additional ﬁndings suggest that both EGFR and HER 2
(two types of growth factor receptors) are associated to lipid-rafts
and that their signaling events are dependent on the cholesterol
content of the lipid-rafts (Chen and Resh, 2002). Once again, the
disruption of the lipid rafts via depletion of circulating choles-
terol levels interferes with the receptor activation and subsequent
inhibition of cell growth and development (Chen and Resh, 2002;
Adam et al., 2007; Elmore, 2007)
Metastasis. The metastatic phenotype of cancer cells is mediated
by signaling mechanisms that decrease cell adhesion and promote
cell migration. Integrins and cell-surface glycoproteins such as
CD44 are essential components of the cell adhesion mechanism.
CD44 is an adhesion molecule expressed in cancer cells, associ-
ated with lipid rafts (Oliferenko et al., 1999; Murai, 2012). The
modulation of cholesterol either by disruption of lipid rafts or by
diminishing plasma levels via statin therapy enhances dissociation
of CD44 from the lipid rafts (Murai, 2012) suggesting that choles-
terol (membrane or circulating levels) may impact the progression
of metastasis.
Cholesterol as a precursor of steroidogenesis
The ﬁve different classes of steroid hormones are synthesized
from a common precursor molecule – cholesterol. The abil-
ity of human cells to synthesize steroid hormones is limited to
specialized organs, the adrenal cortex and the gonads. Steroid
hormones have long been recognized as regulators of cell pro-
liferation and differentiation and are intimately associated with
the etiology of breast and prostate cancers. Androgen depriva-
tion therapy is routinely employed in prostate cancer therapy.
Recently, it has been shown that prostate cancer cells are able
to carry out intracellular synthesis of androgens using cholesterol
as the main precursor (Dillard et al., 2008; Locke et al., 2008).
Considering that the levels of androgen synthesized by prostate
cancer cells seem to be sufﬁcient to activate the androgen receptor
(AR), the acquisition of this capacity is thought to be the funda-
mental mechanism in the development of the androgen resistant
prostate cancer phenotype. In a recent report cholesterol has been
shown to be an essential precursor for the steroid synthesis pro-
cess and as a pathway agonist, facilitating the up-regulation of
steroidogenic gene expression. These ﬁndings are based on the
assessment of steroidogenesis enzymes (CYP17A) that are directly
correlated with the intra-tumoral cholesterol levels (Mostaghel
et al., 2012).
Cholesterol as mediator of inﬂammation
The oxidation and deposition of cholesterol on blood vessels is
a common cause of inﬂammatory response that leads to cardio-
vascular sequelae. The role of oxidized cholesterol in promoting
inﬂammatory responses could be a factor in subsequent events,
including the initiation of carcinogenesis (Pelton et al., 2012).
The oxidation of cholesterol occurs via enzymatic reactions or
by direct interaction with reactive oxygen species (ROS) pro-
ducing oxysterols that play important roles in the regulation of
bile acids and steroid hormones synthesis (Dufour et al., 2012).
Elevated concentrations of oxysterols have been associated with
colon, lung, breast, skin, and bile duct cancers (Dufour et al., 2012;
Silvente-Poirot and Poirot, 2012a), while hypocholesterolemia
decreases the likelihood of oxidation and prostatic inﬂamma-
tion (one of the etiological factors of prostate cancer; Kim et al.,
2012).
CHOLESTEROL TRANSPORT
Cholesterol is a highly insoluble molecule that is transported in
the circulation via endogenous transporters known as lipopro-
teins. Lipoproteins mediate the processing and delivery of dietary
cholesterol to peripheral tissues and help maintaining the homeo-
static balance by removing the excess cholesterol from peripheral
tissues to the liver. It is therefore plausible that lipoproteins play
a fundamental role in cancer progression via supplying malig-
nant cells and tumors with cholesterol (Silvente-Poirot and Poirot,
2012b).
A role for lipoproteins in the promotion of cancer progres-
sion was initially proposed by a number of investigators (Ho et al.,
1978; Vitols et al., 1984, 1990). So far several studies reported the
reduction in the levels of plasma lipoprotein components in can-
cer patients. Originally these changes were described as risk factor
for cancer and hypercholesterolemia was thought to contribute to
cancer development and progression. Subsequently, an alternate
and more plausible rationale has emerged identifying the lowering
of plasma cholesterol values as a consequence of malignant tumor
growth and development that may actually be utilized as marker
for screening undiagnosed cancers (Solomon and Freeman, 2011).
Furthermore, it has also been shown that upon successful remis-
sion blood cholesterol levels were restored to normal values in
cancer patients (Niendorf et al., 1995). When analyzing the lipid
proﬁle of cancer patients among the two major cholesterol trans-
porters (HDL and LDL),HDL levels have consistently been shown
tobe themost affected inmalignant tumordevelopment (Muntoni
et al., 2009).
During periods of rapid growth and development, Low-density
lipoprotein (LDL) particles provide cholesterol to most peripheral
tissues via the LDL-receptor, an endocytotic process involving the
uptake of the whole lipoprotein particle (Brown and Goldstein,
1986). HDL particles, on the other hand play an important role in
removing the excess cholesterol from peripheral tissues, to initiate
reverse transport of cholesterol to the liver. The HDL mediated
reverse cholesterol transport process is essential to facilitate the
liver’s unique ability to process and promote the excretion of excess
cholesterol from the body (Simons and Ikonen, 2000). TheABCA1
transporter facilitates this process promoting the efﬂux of choles-
terol from peripheral tissues for incorporation into HDL particles
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to allow the removal of peripheral cholesterol via lipoprotein
receptors to the liver.
While there is a negative correlation between HDL-cholesterol
levels and cancer risk, plasma cholesterol levels havebeenpositively
correlated with increased expression of cyclin D1, a marker associ-
ated with tumor initiation and progression (Llaverias et al., 2011).
Several additional studies have shown that lipoproteins are capable
of stimulating growth of breast cancer cells in vitro, in addition
to enhancing the aggressiveness of malignant tumors in mouse
models (Danilo and Frank, 2012). Earlier data showed that, addi-
tion of HDL to cell cultures increased the proliferation of human
breast cancer cells (Uda et al., 2011). These ﬁndings are consistent
with several reports on overexpression of the scavenger receptor
class B type 1 (SR-B1) receptor in cancer cells, which suggest that
during the process of carcinogenesis, tumor cells exploit the HDL
mediated removal of cholesterol from peripheral tissues to satisfy
their increased cholesterol requirements.
TARGETING CHOLESTEROL PATHWAYS AS CANCER
THERAPY
Accumulating evidence suggests that cholesterol plays an impor-
tant role in cancer progression and development. Accordingly,
several strategies involving regulatory factors that impact cell
and blood cholesterol levels have been studied. The inhibition
of the mevalonate pathway using statin drugs or biophospho-
nates result in inhibition of tumor growth and proliferation
(Clendening and Penn, 2012; Thurnher et al., 2012). Parallel to
the statins and bisphosphonates, isoprenoids (Mo and Elson,
2006) and particularly tocotrienols suppress tumor growth in vitro
and in vivo (Mo and Elfakhani, 2013) consequent to mevalonate
deprivation.
Similarly, a drug (ezitimibe), known to inhibit cholesterol
absorption by blocking NPC1L1 gut transporters, was shown to
interfere with carcinogenesis (Solomon et al., 2009). In this study
the administration of ezitimibe signiﬁcantly decreased tumor-
associated blood vessel development, apparently via increased
levels of TSP-1, a potent inhibitor of angiogenesis (Solomon
et al., 2009). These and other ﬁndings suggest that decreasing
plasma cholesterol levels may be a plausible therapeutic approach
to cancer therapy. Alternate therapeutic strategies have also been
proposed attempting to take advantage of the high cholesterol
requirements of cancer cells. This strategy relies on “Trojan horse”
approach (Lacko et al., 2007) to deliver anti-cancer agents to cancer
cells and tumors via receptor-mediated mechanism as discussed
below.
LIPOPROTEINS AS DELIVERY VEHICLES IN CANCER
THERAPEUTICS
Lipoproteins share a common structural conﬁguration of a phos-
pholipid monolayer stabilized by a protein meshwork, creating
a stable, sealed inner hydrophobic core. Based on this archi-
tecture, lipoproteins are ideally suited to accommodate and
transport lipophilic compounds, including anti-cancer drugs.
This capability of natural and synthetic lipoprotein structures
is a major advantage for drug delivery, as it allows a stable
hydrophobic environment to accommodate anti-cancer agents
and protect them from rapid removal from the blood circulation
(Counsell and Pohland, 1982; Bijsterbosch and van Berkel, 1990;
Bijsterbosch et al., 1994; Firestone, 1994).
Furthermore, the analysis of several cancer tissues and can-
cer cells revealed the over-expression of speciﬁc components
of cholesterol transport, including the SR-B1 (HDL) receptor
and the LDL-receptor (Lacko et al., 2002; Tatidis et al., 2002;
Llaverias et al., 2011; Gorin et al., 2012). The data showing
elevated SR-B1 expression levels in cancer cells and tumors, com-
bined with the ﬁnding that HDL-cholesterol levels are lower
in cancer patients (compared to normal subjects), suggest that
HDL particles are the major suppliers of cholesterol to can-
cer cells. Based on the SR-B1 receptor mediated drug delivery
concept, our laboratory has developed synthetic/reconstituted
HDL (rHDL) as a drug delivery platform for anti-cancer agents
(Lacko et al., 2002, 2006; McConathy et al., 2008; Mooberry
et al., 2009; Shahzad et al., 2011; Sabnis et al., 2012; Sabnis and
Lacko, 2012). These drug containing rHDL nanoparticles pro-
vide a targeted delivery vehicle with broad therapeutic potential
due to the limited expression of the SR-B1 in normal tissue
and the over-expression of this receptor by the vast majority
of cancer types (Shahzad et al., 2011). The rHDL drug deliv-
ery approach is anticipated to markedly suppress tumor growth
and to limit or eliminate the off target toxicity of drugs used
in cancer chemotherapy (Lacko et al., 2007; Sabnis and Lacko,
2012).
The rHDL delivery of anti-cancer drugs has another potential
advantage associated with the selective uptake mechanism of the
SR-B1 receptor that facilitates the cytoplasmic delivery of rHDL
core components without internalization of the lipoprotein parti-
cle (Mooberry et al., 2009; Ng et al., 2011). This mechanism may
be of particular interest as it avoids the lysozomal environment,
characteristic of the endocytotic pathway, frequent cause of drug
inactivation (Rensen et al., 2001).
CONCLUSIONS
While the impact of cholesterol on oncogenic events, includ-
ing tumor development, cell migration and angiogenesis have
been recognized (Buchwald, 1992; Mo and Elson, 2006, 2008),
the mechanisms underlying the role of cholesterol in these
events is yet to be fully elucidated. The assumption that choles-
terol is primarily required for the high proliferative behavior
of malignant cells is likely to be too restrictive as cholesterol
has also been shown to be essential for the assembly and func-
tion of lipid rafts and related signaling pathways that mediate
carcinogenesis. In addition, cholesterol is known to serve as a
precursor for steroid hormone synthesis, promote cell migra-
tion and mediate of inﬂammatory process, a key contribu-
tor to carcinogenesis. Consequently, targeting cholesterol and
lipoprotein pathways is a potentially powerful strategy for can-
cer therapy. Several studies have explored the inhibition of
cholesterol synthesis via the mevalonate pathway as a therapeu-
tic approach for cancer therapy (Buchwald, 1992). While some
of the evidence from these studies suggests that statin drugs
inhibit carcinogenesis, currently there is no consensus regarding
the long-term clinical beneﬁts of this approach at least par-
tially due to their dose-limiting toxicities (Thibault and Samid,
1996).
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Utilizing lipoprotein transport for the delivery of anti-cancer
agents to cancer cells and tumors is a promising therapeutic
approach (Ng et al., 2011; Sabnis and Lacko, 2012). Impor-
tant features of this concept are the targeted selective tumor
delivery of anti-cancer drugs and the reduction of peripheral
toxicity to normal cells (Ng et al., 2011; Sabnis et al., 2012,
2013; Sabnis and Lacko, 2012). Overall, in our view, the
thorough exploration of the mechanism(s) whereby choles-
terol may impact carcinogenesis and/or metastasis is a key
research topic that should be vigorously pursued in order
to enhance the effectiveness of the current state of cancer
therapeutics.
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